IMPORTANT SAFETY INFORMATION
EYLEA® (aflibercept) Injection is a prescription
medicine administered by injection into the eye. You should
not use EYLEA if you have an infection in or around the eye,
eye pain or redness, or known allergies to any of the
ingredients in EYLEA, including aflibercept.
Injections into the eye with EYLEA can result in an
infection in the eye and retinal detachment (separation of
retina from back of the eye) can occur. Inflammation in the
eye has been reported with the use of EYLEA.
In some patients, injections with EYLEA may cause a
temporary increase in eye pressure within 1 hour of the
injection. Sustained increases in eye pressure have been
reported with repeated injections, and your doctor may
monitor this after each injection.
There is a potential but rare risk of serious and sometimes
fatal side effects, related to blood clots, leading to heart
attack or stroke in patients receiving EYLEA.
The most common side effects reported in patients receiving
EYLEA were increased redness in the eye, eye pain, cataract,
vitreous (gel-like substance) detachment, vitreous floaters,
moving spots in the field of vision, and increased pressure
in the eye.
You may experience temporary visual changes after an EYLEA
injection and associated eye exams; do not drive or use
machinery until your vision recovers sufficiently.
Contact your doctor right away if you think you might be
experiencing any side effects, including eye pain or
redness, light sensitivity, or blurring of vision, after an
For additional safety information, please talk to your
doctor and see the
full Prescribing Information
You are encouraged to report negative side effects of
prescription drugs to the FDA.
www.fda.gov/medwatch, or call 1-800-FDA-1088.
EYLEA® (aflibercept) Injection 2 mg (0.05mL) is a
prescription medicine approved for the treatment of patients
with Wet Age-related Macular Degeneration (AMD), Macular Edema
following Retinal Vein Occlusion (RVO), Diabetic Macular Edema
(DME), and Diabetic Retinopathy (DR).